Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells $133,344.00 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 14,400 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $133,344.00. Following the transaction, the chief executive officer now owns 266,598 shares in the company, valued at $2,468,697.48. The trade was a 5.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

KalVista Pharmaceuticals Stock Performance

KALV opened at $10.15 on Friday. The firm has a market cap of $438.63 million, a P/E ratio of -2.88 and a beta of 0.92. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.39 and a 52-week high of $16.88. The business’s fifty day moving average is $11.04 and its 200-day moving average is $11.99.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.91) by $0.04. On average, research analysts predict that KalVista Pharmaceuticals, Inc. will post -2.7 earnings per share for the current fiscal year.

Institutional Trading of KalVista Pharmaceuticals

Several large investors have recently bought and sold shares of KALV. Vestal Point Capital LP boosted its stake in KalVista Pharmaceuticals by 73.9% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after buying an additional 1,700,000 shares in the last quarter. Capital World Investors acquired a new stake in KalVista Pharmaceuticals in the first quarter valued at about $17,370,000. Great Point Partners LLC acquired a new stake in KalVista Pharmaceuticals in the second quarter valued at about $15,768,000. State Street Corp boosted its stake in KalVista Pharmaceuticals by 68.1% in the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after buying an additional 515,179 shares in the last quarter. Finally, Emerald Advisers LLC boosted its stake in KalVista Pharmaceuticals by 29.8% in the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock valued at $9,681,000 after buying an additional 192,091 shares in the last quarter.

Wall Street Analysts Forecast Growth

KALV has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Monday, October 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th. Finally, Needham & Company LLC reissued a “buy” rating and set a $32.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, September 6th.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).